Key Points {#sec7}
==========

CAR T-cell therapy has shown promising responses in both hematologic and solid cancers. However, there are some limitations awaiting for solutions, such as insufficient quantity and poor quality of autologous T cells, CAR T cell exhaustion and tumor suppressive microenvironments, potential self-killing and uncontrollable proliferation.Genomic editing technologies, especially CRISPR/Cas9 with flexibility, simplicity, high efficiency and multiplexing open a window to develop next-generation CAR T cells.CRISPR/Cas9 genomic editing technology holds promising explorations and applications to create next-generation CAR T cell products, including universal CAR T cells by disrupting endogenous TCR or HLA, more potent CAR T cells by ablating of inhibitory modulators and more controllable CAR T cells by adding inducible safe switches or suicide genes.CRISPR/Cas9 technology is unveiling a new era for CAR T cell therapy.

Introduction {#sec1}
============

Cancer immunotherapy is the fourth mainstream treatment after surgery, chemotherapy and radiotherapy. Adoptive T-cell immunotherapy, particularly chimeric antigen receptor (CAR) T cell therapy, has revolutionized cancer therapy especially after the FDA approval of Kymriah and Yescarta (CD19-directed CAR T cells in B-cell leukemia and lymphoma) \[[@ref1]\]. CARs are synthetic receptors typically containing an antibody-derived target-binding extracellular domain, a hinge region, a transmembrane domain and an intracellular signaling moiety capable of activating T cells \[[@ref4],[@ref5]\]. T cells programmed with CARs can specifically recognize and kill antigen-expressing cells without the restriction of major histocompatibility complex (MHC). Clinical data has demonstrated that CAR T-cell therapy can induce durable complete remissions (CRs) in patients with a variety of hematologic and solid cancers, especially in relapsed/refractory acute lymphoblastic leukemia (ALL) and multiple myeloma with striking response rates of 80--100% \[[@ref6]\]. Despite of promising efficacy of CAR T-cell therapy, there are several challenges awaiting for solutions, such as insufficient quantity and poor quality of autologous T cells, CAR T cell exhaustion and tumor suppressive microenvironments, potential self-killing and uncontrollable proliferation.

Optimization of the CAR T designs is supposed as one of the main tracks to tackle these limitations. The first generation of CAR T cells with only CD3 zeta intracellular chain was found to have modest proliferative and cytotoxic capacity \[[@ref9]\]. The second generation of CARs contains a single costimulatory domain (CD28 or 4-1BB), proven to attain an improved efficacy and *in vivo* survival, whereas the third generation has two or more costimulatory domains (CD28, 4-1BB, ICOS or OX40), not superior to the second generation \[[@ref13]\]. More functional elements are considered to be added to the next generation of CARs, like interleukins genes to increase potency, chemokine receptors genes to improve T-cell trafficking and on--off switches or suicide genes to enhance safety and controllability \[[@ref16]\]. The structures and features of every generation of CAR-T are shown in [Table 1](#TB1){ref-type="table"}.

###### 

Structure and features of every generation of CAR-T

  **Structure of CAR**                                                                            **First-generation CAR**                                            **Second-generation CAR**                                                                  **Third-generation CAR**                    **Next-generation CAR**   **Universal CAR**   
  ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------- ------------------------- ------------------- ------
  Similarities                                                                                    An extracellular antigen-recognition region consisting of an scFv                                                                                                                                                                                        
                                                                                                                                                                       A flexible hinge region derived from a CD8 molecule or CD28 or Fc region of an antibody                                                                                             
                                                                                                                                                                        A transmembrane derived from CD8 or CD28                                                                                                                                           
  Differences                                                                                     Intracellular domain                                                only CD3ζ                                                                                  CD3ζ                                        CD3ζ                      CD3ζ                CD3ζ
  One costimulatory molecule: CD28 or 4-1BB                                                       ≥ 2 Costimulatory molecules: CD28, 4-1BB, ICOS or OX40              One costimulatory molecule: CD28 or 4-1BB                                                  One costimulatory molecule: CD28 or 4-1BB                                                 
  Functional elements: interleukins, chemokine receptors, on-off-switches or suicide genes etc.   Knock-out of TCRs or/and HLAs                                                                                                                                                                                                                            
  *In vivo* Persistence                                                                           Low (days to 2 months)                                              Imporved (3 months to years)                                                               Not superior to 2nd-generation              Exploration               Exploration         
  Antitumor Effects                                                                               Low (ORR 0--40%)                                                    Imporved (ORR depending on the tumor type)                                                 Not superior to second-generation           Exploration               Exploration         

The development of genomic editing technologies opens a window to accelerate the fourth generation of CAR T cells. There are currently three major genomic editing technologies, including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regulatory interspaced short palindromic repeat/CRISPR-associated protein 9 (CRISPR/Cas9) \[[@ref19]\]. Although ZFNs and TALENs have been applied to engineer T cells in clinical trials, the recognition of targetable DNA sequences is based on complicated protein conformation, a pair of Zn-finger binding domains or a pair of TALE DNA binding domains, accompanying with complex designs and relatively low gene-editing efficiencies \[[@ref22],[@ref23]\]. CRISPR/Cas9, directed by a small guide RNA (sgRNA) to the target site, has become the most popular and developed of these tools due to its simplicity, flexibility, high efficiency and multiplexable genome editing capabilities \[[@ref24]\]. A sgRNA-guided Cas9 nuclease induces a DNA double-stranded break at targeted genomic locations, subsequently repaired by non-homologous end joining (NHEJ) or homology-directed repair (HDR). NHEJ, an error prone repair pathway, can result in insertions or deletions of small nucleotide sequences and HDR can knock-in relatively large gene segments in the presence of a homology repair template at the site of interest \[[@ref27]\]. Therefore, the combination with CRISPR/Cas9 technology will further expand the landscape of T-cell engineering. Besides knock-in of functional genes, such as interleukins and suicide genes, to product next-generation CAR T cells, other strategies comprises knock-out of endogenous genes, such as TCRs and MHCs, to develop 'off-the-shelf' universal CAR T cells \[[@ref30]\], disruption of inhibitory receptors (such as PD-1 and TGF beta receptor) to ameliorate suppressive microenvironments \[[@ref31],[@ref32]\], integration of the CAR cassette into the specific gene locus(such as TRAC and TET2) to improve efficiency and safety \[[@ref33],[@ref34]\], deletions of target genes to avoid self-killing of CAR T cells \[[@ref35]\]. CRISPR/Cas9 technology is unveiling a new era for CAR T-cell therapy. All gene-edited CAR T cells discussed here are shown in [Table 2](#TB2){ref-type="table"}.

###### 

Overview of the application of genomic editing technologies in CAR-T cells

  **Target of CAR**   **Delivery of CAR**   **Target locus**            **Gene-editing method**                                                      **Delivery**           **Editing efficiency**   **Reference**
  ------------------- --------------------- --------------------------- ---------------------------------------------------------------------------- ---------------------- ------------------------ ----------------------------------
  CD19                SB electroporation    TRAC and TRBC               ZFNs                                                                         mRNA electrotransfer   15--37%                  \[[@ref33]\]
  CD19                Lentivirus            TRAC and CD52               TALEN                                                                        mRNA electrotransfer   10--60%                  \[[@ref36]\]
  CD19                AAV vector            TRAC (insert CAR to TRAC)   CRISPR/Cas9                                                                  Electroporation        \~70%                    \[[@ref29]\]
  CD19                SB electroporation    HLA-A                       ZFNs                                                                         Nucleofection          40.70%                   \[[@ref40]\]
  CD19                Lentivirus            B2M and TRAC                CRISPR/Cas9                                                                  RNA electroporation    52.55--65.21%            \[[@ref26]\]
  CD19                                      TRAC, B2M and PD-1                                                                                                              37.05--60.97%            
  CD19                Lentivirus            B2M and TRAC                CRISPR/Cas9 (incorporating multiple gRNA cassettes in a single CAR vector)   Lentiviral vector      71.3 ± 6.7%              \[[@ref42]\]
                                            TRAC, B2M and Fas                                                                                                               55.10%                   
                                            TRAC, B2M and PD-1,CTLA-4                                                                                40.10%                                          
  CD19                Lentivirus            TCR and B2M                 CRISPR/Cas9                                                                  RNA electroporation    79.90%                   \[[@ref43]\]
                                            TRBC, B2M and PD-1                                                                                                              /                        
  PSMA                Lentivirus            dnTGF-βRII                  /                                                                            Lentiviral vector      53.20%                   \[[@ref55]\]
  CD19                Retrovirus            IL-15 and an suicide gene   Inducible caspase-9                                                          Retroviral vector      65%                      \[[@ref57]\]
  CD19                Retrovirus            Safety switch               Inducible caspase-9                                                          Retroviral vector      61% ± 5%                 \[[@ref58]\]
  CD19                Lentivirus            GM-CSF                      CRISPR/Cas9                                                                  Lentiviral vector      82.20%                   \[[@ref61]\]
  CD33                Lentivirus            CD33 in HSCs                CRISPR/Cas9                                                                  Electroporation        40--90%                  \[[@ref31], [@ref64], [@ref65]\]
  CD7                 Gammaretrovirus       CD7 in CAR T cells          CRISPR/Cas9                                                                  Electroporation        \>80%                    \[[@ref66]\]

Production of allogeneic universal CAR T cells {#sec2}
----------------------------------------------

Although currently widespread-used autologous CAR T cells have shown promising results in cancer therapy, limitations exist. Almost 10--15% of enrolled patients were unable to receive infusions of CAR T cells because of poor quality and insufficient quantities of autologous T cells unavailable for manufacturing or rapid disease progression and even death before successful production of certain amount of CAR T cells \[[@ref1]\]. A UPenn team recently reported a patient relapsing after infusion of anti-CD19 CAR T cells with CD19-negative leukemia that aberrantly expressed the anti-CD19 CAR because the CAR gene was unintentionally introduced into a single leukemic B cell during T-cell manufacturing \[[@ref36]\]. The development of universal 'off-the-shelf' CAR T cells from healthy donors can circumvent the constraints and potentially be the mainstream direction in the future. The major barriers of such universal CAR T cell products are graft-versus-host disease (GVHD) and rejection of the infused allogeneic T cells. Endogenous αβ T cell receptors (TCRs) on adoptively transferred donor lymphocytes can recognize alloantigens in human leukocyte antigen (HLA) mismatched recipients resulting in GVHD; conversely, recognition of foreign HLA molecules on donor T cells may lead to rejection.

ZFNs and TALENs were successfully used to knock-out TCRα constant (TRAC) and TCRβ constant (TRBC) to generate TCR-negative CAR T cells to prevent GVHD without compromising CAR-mediated cytotoxicity \[[@ref37],[@ref38]\]. Previous researches demonstrated that genetic knock-out of either *TRAC* or *TRBC* loci was sufficient to eliminate expression of αβTCR on the T cell surface \[[@ref39]\]. The Cellectis firstly reported the generation of TALEN-edited allogeneic universal anti-CD19 CAR T(UCART19) cells in which *TRAC* and *CD52* genes were knocked out \[[@ref40]\]. CD52 disruption in the CAR T cells allowed effective targeted depletion of patients' autologous T cells using an anti-CD52 antibody (alemtuzumab). The first-in-man application of the products was two infants with high-risk CD19-positive ALL who achieved molecular remission after receiving the infusion of UCART19 cells and attained successful bridge-to-transplantation \[[@ref41],[@ref42]\]. The remarkable results led to two clinical trials of UCART19 cells: CALM trial in adults and PALL trial in pediatric patients (NCT02746952 and NCT02808442). Pooled data of 20 patients showed acceptable and manageable safety with 15% (3/20) of severe cytokine release syndrome (CRS) and 10% (2/20) of G1 cutaneous acute GVHD as well as promising efficacy with 88% (14/16) of CR or CR with incomplete blood count recovery (CRi) and 86% (12/14) of minimal residual disease-negative \[[@ref43]\]. A MSKCC group showed that directing a CD19-specific CAR to the TRAC locus using CRISPR/Cas9 technology not only minimized the risks of insertional oncogenesis and TCR-induced GVHD, but also enhanced T-cell potency and delayed T-cell exhaustion \[[@ref33]\].

ZFNs were also used to target the HLA-A locus to permanently and completely eliminate HLA-I expression in primary and genetically modified human T cells used in clinical trials to evade rejection \[[@ref44]\]. In addition, elimination of HLA heavy chains or beta-2-microglobulin (*B2M*), the non-polymorphic subunit of HLA-I complex, would prevent rapid rejection of allogeneic cells \[[@ref45]\]. However, ideal universal CAR T cells should be silenced both TCR and HLA to avoid GVHD and rejection without reducing persistence and cytotoxicity *in vivo*. CRISPR/Cas9 has an obvious advantage in simultaneously multiplex and highly efficient genomic editing compared with ZFNs and TALENs. CRISPR/Cas9 was readily applicable to generate double-knock-out (*B2M* and *TRAC*, DKO) UCART19 cells with as similar safety and efficacy as wild-type anti-CD19 CAR T cells in preclinical studies \[[@ref30]\]. One-shot CRISPR protocol for multiplex genome editing by incorporating multiple gRNA cassettes into a single CAR lentiviral vector was developed to generate DKO UCART19 cells \[[@ref46]\]. By combining the lentiviral delivery of CAR with CRISPR RNA electroporation to co-introduce RNA encoding the Cas9 and gRNAs targeting endogenous TCR and B2M concurrently, an improved editing efficiency(\~80%) was acquired to construct the DKO UCART19 cells that showed as potent antitumor activities as non--gene-edited CAR T cells both *in vitro* and in animal models \[[@ref47]\]. However, the issue of whether such HLA-I negative CAR T cells will be the target of NK cells should be considered. Administering an anti-NK cell depletion antibody or engineering T cells with HLA-E are potential solutions to circumvent NK-mediated rejection \[[@ref44], [@ref48]\].

Recent advances in gene-editing technology, especially CRISPR/Cas9, allow for the production of universal CAR T cells starting from healthy donor in which the manufacture and quality of T cells can be preselected as well as GVHD and rejection can be avoided. The CRISPR/Cas9-modified universal CAR T cells need to be further tested for the safety and efficacy in clinical studies and there are currently six relevant ongoing clinical trials ([Table 3](#TB3){ref-type="table"}).

###### 

Current clinical trials about universal CAR T cells

  **CAR target**   **Gene-editing technology**   **Locus of knock-out**   **Diseases**                           **Phase**   **R&D Unit**                       **Study location**   **NCT ID**
  ---------------- ----------------------------- ------------------------ -------------------------------------- ----------- ---------------------------------- -------------------- -------------------------------------
  CD19             TALENs                        TCR and CD52             B-ALL                                  1           Servier Group company              America, Europe      NCT02808442 NCT02735083 NCT02746952
  CD19             CRISPR/Cas9                   TRAC and HLA-I           ALL and NHL                            1/2         Shanghai Bioray Laboratory Inc.    China                NCT03229876
  CD19             CRISPR/Cas9                   TRAC and B2M             B cell leukemia and lymphoma           1/2         Chinese PLA General Hospital       China                NCT03166878
  CD19             CRISPR/Cas9                   TCR and CD52             RR DLBCL                               1           Nanjing Bioheng Biotech Co., Ltd   China                NCT04026100
  CD123            TALENs                        TCR and CD52             RR and Newly Diagnosed High-risk AML   1           Cellectis S.A.                     Europe               NCT04106076 NCT03190278
  CD123            TALENs                        TCR and CD52             RR BPDCN                               1           Cellectis S.A.                     America              NCT03203369
  BCMA             CRISPR/Cas9                   TRAC and HLA-I           Multiple Myeloma                       1/2         Shanghai Bioray Laboratory Inc.    China                NCT03752541

NHL, Non-Hodgkin lymphoma; RR, refractory or relapsed; DLBCL, diffuse large B-cell lymphoma; BPDCN, blastic plasmacytoid dendritic cell neoplasm.

Disruption of inhibitory signaling molecules {#sec3}
--------------------------------------------

The function of T cells was proven to play a significantly important role in the therapeutic effect of CAR T cells \[[@ref49]\]. However, T cells are exposed to persistent antigen in patients with malignant tumors, resulting in T-cell exhaustion \[[@ref50]\]. Exhausted T cells lose robust effector functions and express multiple inhibitory receptors, such as programmed cell death 1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), domain-containing protein-3 (TIM-3) and lymphocyte-activated gene-3 (LAG-3), which inhibit T-cell proliferation and cytokine production leading to immune escape \[[@ref51]\]. The inhibitory pathways also contribute to suppressive tumor microenvironment, a major barrier of CAR T-cell therapy in solid tumors. Immune checkpoint inhibitors, anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, have shown promising clinical results and been approved by the FDA \[[@ref52]\]. Thus, disruption of multiple inhibitory factors is expected to improve the potency of CAR T cells. Recent studies suggested that anti-CD19 CAR T cells with CRISPR-mediated triple-knock-out of the TRAC/TRBC, B2M and PD-1 genes displayed stronger antitumor functions in contrast to DKO UCART19 cells *in vitro* and in animal models \[[@ref30],[@ref47]\]. High-fidelity Cas9s with the one-shot platform showed the feasibility of generating PD-1 and CTLA-4 dual inhibitory pathway-resistant DKO UCART19 cells by simultaneous disruption of quadruple genes \[[@ref46]\].

The Fas receptor is a member of the tumor necrosis factor α (TNF-α) family of death receptors that mediate cell death \[[@ref53]\]. Researches demonstrated that CAR T cell activity was attenuated due to cell Fas-FasL-dependent activation-induced cell death (AICD) \[[@ref54]\]. Ren *et al*. \[[@ref46]\] also utilized CRISPR/Cas9 technology to generate Fas-resistant universal CAR T cells that observed elevation of AICD resistance and prolonged survival.

Transforming growth factor-β (TGF-β) represses effector T-cell activities through binding the TGF-β receptors (TGFBRI and TGFBRII) to induce heterodimerization of the respective receptors and phosphorylation of the major TGF-β signal mediators SMAD2 and SMAD3, resulting in reduced cytokine production, cytotoxicity and amplification \[[@ref55]\]. TGF-β also drives T-cell differentiation into regulatory T cells (Tregs) \[[@ref56]\]. Thus, inhibiting TGF-β signaling, a potent immunosuppressive factor in a variety of solid tumors, has the potential to improve the immunosuppressive milieu. Previous studies demonstrated that TGF-β pathway could be blocked by using a dominant-negative TGFΒRII (dnTGF-βRII), which lacked the intracellular domain necessary for downstream signaling \[[@ref57]\]. Foster *et al*. \[[@ref31]\] used a clinical grade retrovirus vector to construct dnTGF-βRII-expressing human antigen-specific cytotoxic T lymphocytes (CTLs) and found that TGF-β-resistant CTLs had a functional advantage over unmodified CTLs in the TGF-β-secreting lymphoma \[[@ref31]\]. The clinical trial (NCT00368082) showed that TGF-β-resistant CTLs could safely expand and persist in patients with Hodgkin lymphoma without lymphodepleting chemotherapy and induced complete responses \[[@ref58]\]. It was testified that adding dnTGF-βRII to PSMA-targeted human CAR T cells promoted T-cell proliferation and augmented prostate cancer eradication \[[@ref59]\]. Chang *et al*. recently described a novel TGF-β CAR containing a scFv based on the sequences of TGF-β-neutralizing antibodies, demonstrating the ability to not only inhibit endogenous TGF-β signaling but also convert TGF-β into a stimulant of T-cell growth \[[@ref60]\]. Above results support the potential value of the countermeasure of using CRISPR/Cas9 technology to generate TGF-β-resistant CAR T or UCART cells to improve potency of engineering T cells in solid tumors.

Exploration of safer and more controllable novel CAR T cells {#sec4}
------------------------------------------------------------

Albeit unprecedented efficacy of CAR T-cell therapy, it is accompanied by serious and even life-threatening toxicities, including CRS, on-target/off-tumor toxicity, neurotoxicity, macrophage activation syndrome/ hemophagocytic lymphohistiocytosis and tumor lysis syndrome, which need to be paid more attention \[[@ref61]\]. The most significant and common toxicity of CAR T-cell therapy is CRS, an inflammatory syndrome caused by multiple cytokines, including interferon γ, interleukin (IL)-1, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α and granulocyte/macrophage colony-stimulating factor (GM-CSF), produced by the CAR T cells themselves and by other cells \[[@ref62]\]. Tocilizumab, IL-6 receptor blockade, was approved by FDA for treatment of CAR T cell-induced severe or life-threatening CRS \[[@ref63]\]. Thus, blocking relevant cytokines signaling is a hopeful strategy to ameliorate the dilemma and CRISPR/Cas9 can effectively knock-out related molecules. Sterner *et al*. \[[@ref64]\] described CRISPR/Cas9 mediated knock-out of GM-CSF and showed that GM-CSF-negative CAR T cells produced less GM-CSF without weakening antitumor activity *in vivo* compared to wild-type CAR T cells. Single or combined knock-out of other critical relevant cytokines in CAR T cells using CRISPR/Cas9 are needed to be further explored. Long-lasting B cell aplasia is a classical on-target/off-tumor toxicity of anti-CD19 and anti-CD20 CAR T-cell therapy \[[@ref65], [@ref66]\]. The insert of safety switches gene into CAR vector is a feasible method to terminate the effects without jeopardizing clinical responses. Diaconu *et al*. \[[@ref67]\] demonstrated that the iC9 safety switch eliminated CD19-specific CAR T cells in a dose-dependent manner in a humanized mouse model, allowing either a selective containment of CAR T expansion in case of CRS or complete deletion on demand granting normal B-cell reconstitution.

There are two reported cases indicating the risks of unexpected situations in the manufacture of CAR T cells and potential carcinogenicity *in vivo*. One CD19-negative relapsed patient after CD19-targeted CAR T cell therapy was found that the CAR gene was unintentionally introduced into a single dominantly-proliferative leukemic B cell and its product bound in cis to the CD19 epitope on the surface of leukemic cells, masking it from recognition by CAR T cells \[[@ref36]\]. Another case was a 78-year-old man with advanced relapsed/refractory chronic lymphocytic leukemia who obtained CR after the second infusion. Unexpectedly, 94% of CAR T cells at the peak of the response originated from a single clone in which lentiviral vector-mediated insertion of the CAR transgene disrupted the methylcytosine dioxygenase TET2 gene \[[@ref34]\]. Therefore, there is a need to incorporate inducible safe switches or suicide genes into the CAR T cells, which can provide a means to eliminate the CAR T cells in case of unexpected toxicities. Hoyos *et al*. \[[@ref68]\] generated a novel anti-CD19 CAR construct that incorporates the IL-15 gene and an inducible caspase-9(iC9)-based suicide gene and \>95% of transgenic cells could be efficiently eliminated within 24 h upon pharmacologic activation of the suicide gene \[[@ref68]\]. Adding inducible safe switches or suicide genes to generate more controllable and safer CAR T cells will be widespread-used by multiplexed CRISPR/Cas9 technology. There are three ongoing clinical trials (NCT02107963, NCT01822652 and NCT02439788) incorporating the iC9 construct into CAR T-cell products to provide a method to eliminate autologous CAR T cells in case of potential off-target toxicity.

Other applications {#sec5}
------------------

CAR T-cells therapy has an obvious barrier in acute myeloid leukemia (AML) because myeloid-directed immunotherapy will eradicate normal as well as malignant cells, leading to bone marrow failure, as has been shown in several preclinical studies of CD33 or CD123 directed CAR T cell therapy \[[@ref69], [@ref70]\]. Several groups developed a novel approach to circumvent the problem with potent anti-CD33 CAR T cells followed by infusions of CRISPR/Cas9-modified CD33-konckout normal hematopoietic stem cells (HSCs), thus allowing persistent antigen-specific cytotoxicity along with reconstitution of effective hematopoiesis \[[@ref35],[@ref71],[@ref72]\]. Extending the success of CAR T cells to T-cell malignancies is also problematic because most target antigens are expressed on both normal and malignant cells, resulting in CAR T-cell fratricide. CD7 is a transmembrane protein highly expressed in T-cell acute leukemia (T-ALL) and largely confined to T cells and natural killer cells. Studies showed that CD7-specific CAR T cell impaired expansion due to self-killing of the CAR T cells. Diogo *et al*. \[[@ref73]\] explored that targeted disruption of the CD7 gene using CRISPR/Cas9 prior to CAR expression minimized fratricide in T cells and allowed the expansion of the CD7-knock-out anti-CD7 CAR T cells with robust antitumor activity for preclinical and potential clinical application. Hence, the CRISPR/Cas9 system can be applied to disrupt the targeted antigens to avoid self-killing of the CAR T cells and broaden the therapeutic index.

Conclusion and outlooks {#sec6}
=======================

The unprecedented responses of CAR T cells in advanced malignancies promote the rapid growth of the therapeutic approach and the development of the smarter and commercialized CAR T cells is an inevitable mainstream trend, such as a split, universal and programmable CAR system to prevent relapse, mitigate overactivation and enhance specificity \[[@ref74]\]. CRISPR/Cas9 genomic editing technology holds promising explorations and applications to create the next-generation CAR T-cell products, including universal CAR T cells by disrupting endogenous TCR and HLA, more potent CAR T cells by ablating inhibitory modulators, more controllable CAR T cells by adding inducible safe switches or suicide genes and novel CAR T cells by knock-out of the targeted antigens to avoid self-killing.

However, the gene-editing specificity and efficiency of CRISPR/Cas9 technology are of significant importance in therapeutic application. The first concern of CRISPR/Cas9 gene editing is off-target effects, which introduce random mutations, hence activating oncogenes or impacting tumor-suppressor genes to unintentional deleterious consequences \[[@ref75]\]. Multiple strategies, such as careful selection of the target site, optimized sgRNA design and Cas9 activity, prior off-target detection assays, have been attempted to minimize the safe risks of off-target effects \[[@ref76]\]. Attempts to increase HR frequencies using HR enhancers or NHEJ inhibitors are currently ongoing and may further promote precise gene engineering \[[@ref79], [@ref80]\]. Another challenge for therapeutic gene editing is efficient and nontoxic delivery into CAR T cells. There are three main methods to deliver CRISPR/Cas9 system, including a DNA plasmid-based system, an all-RNA-based system and a Cas9 ribonucleoprotein complex as delivery \[[@ref81]\]. Viral vectors with high efficiency and potential hazards, such as mutagenesis, immunogenicity and off-target effects, are widely applied for donor DNA delivery and electroporation has emerged as new method to deliver CRISPR/Cas9 elements with safety, simplicity and flexibility \[[@ref82]\]. Viral and non-viral vectors have specific merits and beneficial combinations of different delivery means are being explored to ensure efficiency and safety \[[@ref33]\]. As technical progresses to reduce off-target effects and improve delivery efficiency, CRISPR/Cas9 technology provides an extraordinary potential to construct novel CAR T cells and streamlines the burgeoning realm of immunotherapy.
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